Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on ADMA Biologics, maintaining a $20 price target.
September 20, 2024 | 3:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on ADMA Biologics, maintaining a $20 price target, indicating confidence in the company's future performance.
The reiteration of an Overweight rating and a $20 price target by a reputable analyst suggests a positive outlook for ADMA Biologics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100